FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

Seiji Wakao, JPMorgan, queried the feasibility of achieving ¥1 trillion in oncology revenue amid Datroway’s setbacks. Ogawa stated that ENHERTU’s performance could potentially fill the gap, with a ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...

Enhertu (fam-trastuzumab deruxtecan-nxki) can cause side effects that range from mild to serious. More common side effects include hair loss, nausea, and vomiting. If Enhertu side effects become ...

AstraZeneca (AZN) and Daiichi Sankyo's (DSKYF) drug Enhertu has been approved by the FDA for the treatment of certain breast cancer patients. Read more here.

Trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) is a HER2-directed antibody-drug conjugate. The agent is approved in the United States for several indications, including treatment of ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application (sBLA) seeking approval for expanded use of Enhertu (trastuzumab ...